In a significant strategic shift, Soleno Therapeutics has formally withdrawn its marketing authorization application for VIOKAT in Europe, according to a securities filing submitted on Tuesday. This decision comes just one day after the company announced it had entered into a definitive agreement to be acquired by Neurocrine Biosciences in a transaction valued at approximately $2.9 billion.
Acquisition Details and Strategic Rationale
Neurocrine Biosciences has agreed to acquire Soleno for $53 per share in cash, representing a substantial premium of 34% over Soleno's closing price on April 2 and 51% above its average trading price over the preceding month. The acquisition, which both companies anticipate closing within approximately 90 days subject to customary conditions including shareholder approval and antitrust clearance, will be financed through Neurocrine's existing cash reserves and a modest amount of prepayable debt. The agreement includes a termination clause if the transaction is not completed by October 5.
The withdrawal of the European application halts a regulatory review process that Soleno had previously projected could conclude by mid-2026. In its filing, Soleno cited "business and strategic considerations" for the decision, leaving open the possibility of a future resubmission while cautioning that such a move is not guaranteed. This represents a notable reversal from the company's position in February, when CEO Anish Bhatnagar informed investors of plans to pursue international approvals, beginning with the European Union.
Focus on Vykat XR and U.S. Market
At the center of this transaction is Vykat XR (known as VIOKAT in Europe), Soleno's first and only marketed product. The drug received U.S. Food and Drug Administration approval in March 2025 as the first therapy specifically targeting hyperphagia—the persistent, insatiable hunger associated with Prader-Willi syndrome. This condition affects an estimated 10,000 diagnosed patients in the United States and can lead to dangerous obesity, diabetes, and related health complications.
Vykat XR generated $190.4 million in net sales during 2025, with $91.7 million of that total coming in the fourth quarter alone. Neurocrine CEO Kyle Gano has characterized the drug as "a potential blockbuster in the making," and the acquisition is seen as strengthening Neurocrine's rare-disease portfolio, which already includes Ingrezza and Crenessity.
Market Reaction and Analyst Commentary
Soleno's shares surged nearly 33% following the announcement of the acquisition deal. Analyst commentary has been broadly positive, with RBC's Brian Abrahams describing the transaction as "a third leg to the story" for Neurocrine. Cantor Fitzgerald analyst Josh Schimmer has projected that annual sales for Vykat XR could exceed $1 billion by 2029, highlighting the drug's significant commercial potential.
Bhatnagar has expressed confidence in the strategic fit, calling Neurocrine "the right strategic partner" for expanding access to Vykat XR. However, the withdrawal of the European application narrows one immediate avenue for geographic expansion. Neurocrine has stated it currently has no plans for a European launch, instead focusing commercial efforts on the U.S. market.
European Regulatory Background
The European Medicines Agency had accepted Soleno's marketing authorization application for review in May of the previous year. The company had highlighted a potential patient population of approximately 9,500 individuals across the five largest EU countries and the prospect of up to a decade of market exclusivity for the rare-disease treatment upon regulatory approval. The now-halted review was anticipated to conclude around mid-2026.
The decision to withdraw the application eliminates what could have been a significant mid-2026 catalyst for the company. It also reflects a strategic prioritization by Neurocrine to concentrate resources on the established U.S. commercial opportunity rather than pursuing near-term regulatory efforts in Europe.
This development underscores the strategic recalibrations that often follow major pharmaceutical acquisitions, as acquiring companies reassess and integrate pipeline priorities. For Neurocrine, the immediate focus will be on completing the acquisition and maximizing the U.S. commercial potential of Vykat XR, while the European opportunity remains a longer-term strategic question.
